Show simple item record

dc.contributor.authorSafikhani, Zhalehen_US
dc.contributor.authorEl-Hachem, Nehmeen_US
dc.contributor.authorQuevedo, Reneen_US
dc.contributor.authorSmirnov, Petren_US
dc.contributor.authorGoldenberg, Annaen_US
dc.contributor.authorJuul Birkbak, Nicolaien_US
dc.contributor.authorMason, Christopheren_US
dc.contributor.authorHatzis, Christosen_US
dc.contributor.authorShi, Lemingen_US
dc.contributor.authorAerts, Hugo JWLen_US
dc.contributor.authorQuackenbush, Johnen_US
dc.contributor.authorHaibe-Kains, Benjaminen_US
dc.date.accessioned2016-08-09T14:52:43Z
dc.date.issued2016en_US
dc.identifier.citationSafikhani, Z., N. El-Hachem, R. Quevedo, P. Smirnov, A. Goldenberg, N. Juul Birkbak, C. Mason, et al. 2016. “Assessment of pharmacogenomic agreement.” F1000Research 5 (1): 825. doi:10.12688/f1000research.8705.1. http://dx.doi.org/10.12688/f1000research.8705.1.en
dc.identifier.issn2046-1402en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27822178
dc.description.abstractIn 2013 we published an analysis demonstrating that drug response data and gene-drug associations reported in two independent large-scale pharmacogenomic screens, Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), were inconsistent. The GDSC and CCLE investigators recently reported that their respective studies exhibit reasonable agreement and yield similar molecular predictors of drug response, seemingly contradicting our previous findings. Reanalyzing the authors’ published methods and results, we found that their analysis failed to account for variability in the genomic data and more importantly compared different drug sensitivity measures from each study, which substantially deviate from our more stringent consistency assessment. Our comparison of the most updated genomic and pharmacological data from the GDSC and CCLE confirms our published findings that the measures of drug response reported by these two groups are not consistent. We believe that a principled approach to assess the reproducibility of drug sensitivity predictors is necessary before envisioning their translation into clinical settings.en
dc.language.isoen_USen
dc.publisherF1000Researchen
dc.relation.isversionofdoi:10.12688/f1000research.8705.1en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926729/pdf/en
dash.licenseLAAen_US
dc.subjectArticlesen
dc.subjectBioinformaticsen
dc.subjectGenomicsen
dc.subjectMethods for Diagnostic & Therapeutic Studiesen
dc.subjectMolecular Pharmacologyen
dc.subjectPharmacogenomicsen
dc.subjectPharmacokinetics & Drug Deliveryen
dc.subjectStatistical Methodologies & Health Informaticsen
dc.subjectCancer Cell Linesen
dc.subjectHigh-Throughput Screeningen
dc.subjectBiomarkersen
dc.subjectDrug Responseen
dc.subjectExperimental Designen
dc.subjectStatisticsen
dc.titleAssessment of pharmacogenomic agreementen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalF1000Researchen
dash.depositing.authorAerts, Hugo JWLen_US
dc.date.available2016-08-09T14:52:43Z
dc.identifier.doi10.12688/f1000research.8705.1*
dash.authorsorderedfalse
dash.contributor.affiliatedAerts, Hugo


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record